Frank Truslow - Karuna Therapeutics Senior Development
| KRTXDelisted Stock | USD 203.11 1.46 0.71% |
Executive
Frank Truslow is Senior Development of Karuna Therapeutics
| Phone | 857 449 2244 |
| Web | https://www.karunatx.com |
Karuna Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2471) % which means that it has lost $0.2471 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3644) %, meaning that it created substantial loss on money invested by shareholders. Karuna Therapeutics' management efficiency ratios could be used to measure how well Karuna Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Karuna Therapeutics currently holds 16.69 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Karuna Therapeutics has a current ratio of 17.41, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Karuna Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Debra DursoBumpus | Blueprint Medicines Corp | 55 | |
| Keith White | Amylyx Pharmaceuticals | N/A | |
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| Julian Baker | Blueprint Medicines Corp | 58 | |
| Lucia Celona | Dyne Therapeutics | 59 | |
| Tammy Sarnelli | Amylyx Pharmaceuticals | N/A | |
| Christina Rossi | Blueprint Medicines Corp | 47 | |
| Caroline MD | Apellis Pharmaceuticals | 57 | |
| David Acheson | Apellis Pharmaceuticals | N/A | |
| Linda Arsenault | Amylyx Pharmaceuticals | N/A | |
| MBA MD | X4 Pharmaceuticals | 62 | |
| Matt Yang | Cytokinetics | N/A | |
| Prof MD | Day One Biopharmaceuticals | 55 | |
| Ariel Hurley | Blueprint Medicines Corp | 51 | |
| JD Esq | Apellis Pharmaceuticals | 52 | |
| Emil MD | Terns Pharmaceuticals | 45 | |
| Bo Kara | Mereo BioPharma Group | N/A | |
| Diana Chung | Terns Pharmaceuticals | N/A | |
| Debra Sieminski | Terns Pharmaceuticals | N/A | |
| John Moore | Edgewise Therapeutics | 60 | |
| John Stubenrauch | Day One Biopharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.36 | |||
| Return On Asset | -0.25 |
Karuna Therapeutics Leadership Team
Elected by the shareholders, the Karuna Therapeutics' board of directors comprises two types of representatives: Karuna Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Karuna. The board's role is to monitor Karuna Therapeutics' management team and ensure that shareholders' interests are well served. Karuna Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Karuna Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alexis Smith, Vice Relations | ||
| Stephen Brannan, Chief Medical Officer | ||
| Andrew Miller, Founder Development | ||
| William Meury, CEO President | ||
| Frank Truslow, Senior Development | ||
| Mia JD, General Counsel | ||
| Ronald MD, Senior Medical | ||
| William Kane, Chief Officer | ||
| Alan Breier, Chair Advisor | ||
| Troy Ignelzi, CFO Sec | ||
| Charmaine Lykins, Chief Officer | ||
| Steven MD, Pres CEO | ||
| Jonathan Rosin, Chief Officer | ||
| Jason Brown, Chief Officer |
Karuna Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Karuna Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.36 | |||
| Return On Asset | -0.25 | |||
| Operating Margin | (755.64) % | |||
| Current Valuation | 11.35 B | |||
| Shares Outstanding | 38.2 M | |||
| Shares Owned By Insiders | 4.98 % | |||
| Shares Owned By Institutions | 86.32 % | |||
| Number Of Shares Shorted | 1.97 M | |||
| Price To Earning | (19.88) X | |||
| Price To Book | 10.05 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Karuna Stock
If you are still planning to invest in Karuna Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Karuna Therapeutics' history and understand the potential risks before investing.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |